nasdaq:omed
|
84273
|
Mar 23rd, 2024 12:00AM
|
OncoMed Pharmaceuticals
|
5.0K
|
34.00
|
Open
|
|
Mar 23rd, 2024 12:02AM
|
Mar 23rd, 2024 07:11PM
|
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence.
We are leveraging our understanding of cancer stem cell pathways and immuno-oncology targets to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. OncoMed currently has seven internally discovered drug candidates in clinical development, as well as several active research programs undergoing preclinical evaluation.
To support the advancement of our clinical-stage candidates and our continued discovery efforts, OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline. Since our founding in August 2004, we have raised more than $600 million, more than half of which has come from collaboration funding from our pharmaceutical partnerships.
|
Open
|
oncology, drug development, biotechnology, biopharmaceuticals, immuno-oncology, cancer stem cells, Redwood City, innovation, science, lung cancer, and pancreatic cancer
|
Open
|
800 Chesapeake Dr.
|
Redwood City
|
CA
|
US
|
94063
|
|
OncoMed Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:omed
|
84273
|
Mar 22nd, 2024 12:00AM
|
OncoMed Pharmaceuticals
|
5.0K
|
34.00
|
Open
|
|
Mar 21st, 2024 11:53PM
|
Mar 22nd, 2024 07:00PM
|
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence.
We are leveraging our understanding of cancer stem cell pathways and immuno-oncology targets to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. OncoMed currently has seven internally discovered drug candidates in clinical development, as well as several active research programs undergoing preclinical evaluation.
To support the advancement of our clinical-stage candidates and our continued discovery efforts, OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline. Since our founding in August 2004, we have raised more than $600 million, more than half of which has come from collaboration funding from our pharmaceutical partnerships.
|
Open
|
oncology, drug development, biotechnology, biopharmaceuticals, immuno-oncology, cancer stem cells, Redwood City, innovation, science, lung cancer, and pancreatic cancer
|
Open
|
800 Chesapeake Dr.
|
Redwood City
|
CA
|
US
|
94063
|
|
OncoMed Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:omed
|
84273
|
Mar 21st, 2024 12:00AM
|
OncoMed Pharmaceuticals
|
5.0K
|
34.00
|
Open
|
|
Mar 21st, 2024 12:06AM
|
Mar 21st, 2024 05:43PM
|
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence.
We are leveraging our understanding of cancer stem cell pathways and immuno-oncology targets to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. OncoMed currently has seven internally discovered drug candidates in clinical development, as well as several active research programs undergoing preclinical evaluation.
To support the advancement of our clinical-stage candidates and our continued discovery efforts, OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline. Since our founding in August 2004, we have raised more than $600 million, more than half of which has come from collaboration funding from our pharmaceutical partnerships.
|
Open
|
oncology, drug development, biotechnology, biopharmaceuticals, immuno-oncology, cancer stem cells, Redwood City, innovation, science, lung cancer, and pancreatic cancer
|
Open
|
800 Chesapeake Dr.
|
Redwood City
|
CA
|
US
|
94063
|
|
OncoMed Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:omed
|
84273
|
Mar 20th, 2024 12:00AM
|
OncoMed Pharmaceuticals
|
5.0K
|
34.00
|
Open
|
|
Mar 20th, 2024 12:46AM
|
Mar 20th, 2024 07:44PM
|
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence.
We are leveraging our understanding of cancer stem cell pathways and immuno-oncology targets to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. OncoMed currently has seven internally discovered drug candidates in clinical development, as well as several active research programs undergoing preclinical evaluation.
To support the advancement of our clinical-stage candidates and our continued discovery efforts, OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline. Since our founding in August 2004, we have raised more than $600 million, more than half of which has come from collaboration funding from our pharmaceutical partnerships.
|
Open
|
oncology, drug development, biotechnology, biopharmaceuticals, immuno-oncology, cancer stem cells, Redwood City, innovation, science, lung cancer, and pancreatic cancer
|
Open
|
800 Chesapeake Dr.
|
Redwood City
|
CA
|
US
|
94063
|
|
OncoMed Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:omed
|
84273
|
Mar 19th, 2024 12:00AM
|
OncoMed Pharmaceuticals
|
5.0K
|
34.00
|
Open
|
|
Mar 18th, 2024 11:41PM
|
Mar 19th, 2024 06:16PM
|
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence.
We are leveraging our understanding of cancer stem cell pathways and immuno-oncology targets to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. OncoMed currently has seven internally discovered drug candidates in clinical development, as well as several active research programs undergoing preclinical evaluation.
To support the advancement of our clinical-stage candidates and our continued discovery efforts, OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline. Since our founding in August 2004, we have raised more than $600 million, more than half of which has come from collaboration funding from our pharmaceutical partnerships.
|
Open
|
oncology, drug development, biotechnology, biopharmaceuticals, immuno-oncology, cancer stem cells, Redwood City, innovation, science, lung cancer, and pancreatic cancer
|
Open
|
800 Chesapeake Dr.
|
Redwood City
|
CA
|
US
|
94063
|
|
OncoMed Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:omed
|
84273
|
Mar 18th, 2024 12:00AM
|
OncoMed Pharmaceuticals
|
5.0K
|
34.00
|
Open
|
|
Mar 18th, 2024 12:02AM
|
Mar 18th, 2024 07:29PM
|
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence.
We are leveraging our understanding of cancer stem cell pathways and immuno-oncology targets to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. OncoMed currently has seven internally discovered drug candidates in clinical development, as well as several active research programs undergoing preclinical evaluation.
To support the advancement of our clinical-stage candidates and our continued discovery efforts, OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline. Since our founding in August 2004, we have raised more than $600 million, more than half of which has come from collaboration funding from our pharmaceutical partnerships.
|
Open
|
oncology, drug development, biotechnology, biopharmaceuticals, immuno-oncology, cancer stem cells, Redwood City, innovation, science, lung cancer, and pancreatic cancer
|
Open
|
800 Chesapeake Dr.
|
Redwood City
|
CA
|
US
|
94063
|
|
OncoMed Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:omed
|
84273
|
Mar 16th, 2024 12:00AM
|
OncoMed Pharmaceuticals
|
5.0K
|
35.00
|
Open
|
|
Mar 15th, 2024 11:32PM
|
Mar 16th, 2024 07:16PM
|
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence.
We are leveraging our understanding of cancer stem cell pathways and immuno-oncology targets to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. OncoMed currently has seven internally discovered drug candidates in clinical development, as well as several active research programs undergoing preclinical evaluation.
To support the advancement of our clinical-stage candidates and our continued discovery efforts, OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline. Since our founding in August 2004, we have raised more than $600 million, more than half of which has come from collaboration funding from our pharmaceutical partnerships.
|
Open
|
oncology, drug development, biotechnology, biopharmaceuticals, immuno-oncology, cancer stem cells, Redwood City, innovation, science, lung cancer, and pancreatic cancer
|
Open
|
800 Chesapeake Dr.
|
Redwood City
|
CA
|
US
|
94063
|
|
OncoMed Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:omed
|
84273
|
Mar 15th, 2024 12:00AM
|
OncoMed Pharmaceuticals
|
5.0K
|
35.00
|
Open
|
|
Mar 15th, 2024 01:21AM
|
Mar 15th, 2024 09:06AM
|
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence.
We are leveraging our understanding of cancer stem cell pathways and immuno-oncology targets to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. OncoMed currently has seven internally discovered drug candidates in clinical development, as well as several active research programs undergoing preclinical evaluation.
To support the advancement of our clinical-stage candidates and our continued discovery efforts, OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline. Since our founding in August 2004, we have raised more than $600 million, more than half of which has come from collaboration funding from our pharmaceutical partnerships.
|
Open
|
oncology, drug development, biotechnology, biopharmaceuticals, immuno-oncology, cancer stem cells, Redwood City, innovation, science, lung cancer, and pancreatic cancer
|
Open
|
800 Chesapeake Dr.
|
Redwood City
|
CA
|
US
|
94063
|
|
OncoMed Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:omed
|
84273
|
Mar 14th, 2024 12:00AM
|
OncoMed Pharmaceuticals
|
5.0K
|
35.00
|
Open
|
|
Mar 13th, 2024 11:30PM
|
Mar 14th, 2024 12:27PM
|
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence.
We are leveraging our understanding of cancer stem cell pathways and immuno-oncology targets to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. OncoMed currently has seven internally discovered drug candidates in clinical development, as well as several active research programs undergoing preclinical evaluation.
To support the advancement of our clinical-stage candidates and our continued discovery efforts, OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline. Since our founding in August 2004, we have raised more than $600 million, more than half of which has come from collaboration funding from our pharmaceutical partnerships.
|
Open
|
oncology, drug development, biotechnology, biopharmaceuticals, immuno-oncology, cancer stem cells, Redwood City, innovation, science, lung cancer, and pancreatic cancer
|
Open
|
800 Chesapeake Dr.
|
Redwood City
|
CA
|
US
|
94063
|
|
OncoMed Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:omed
|
84273
|
Mar 13th, 2024 12:00AM
|
OncoMed Pharmaceuticals
|
5.0K
|
35.00
|
Open
|
|
Mar 12th, 2024 11:25PM
|
Mar 13th, 2024 10:58AM
|
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence.
We are leveraging our understanding of cancer stem cell pathways and immuno-oncology targets to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. OncoMed currently has seven internally discovered drug candidates in clinical development, as well as several active research programs undergoing preclinical evaluation.
To support the advancement of our clinical-stage candidates and our continued discovery efforts, OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline. Since our founding in August 2004, we have raised more than $600 million, more than half of which has come from collaboration funding from our pharmaceutical partnerships.
|
Open
|
oncology, drug development, biotechnology, biopharmaceuticals, immuno-oncology, cancer stem cells, Redwood City, innovation, science, lung cancer, and pancreatic cancer
|
Open
|
800 Chesapeake Dr.
|
Redwood City
|
CA
|
US
|
94063
|
|
OncoMed Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|